Paris, September 09th, 2010

First step towards Initial Public Offering on the Paris NYSE Euronext market

STENTYS files its « Document de Base » with the French Autorité des marchés financiers

STENTYS, a medical technology company which has developed a new generation of innovative stents to treat Acute Myocardial Infarction (AMI), announces the filing of its “Document de Base” by the Autorité des marchés financiers (AMF), the French market regulator, under registration n° I.-10- 067 dated 09th September 2010. This is the first step towards the Initial Public Offering of its shares on the Paris NYSE Euronext market.

Founded in 2006, by Professor Jacques Séguin and Gonzague Issenmann, STENTYS is a medical technology company that offers innovative solutions for the treatment of complex coronary diseases. STENTYS offers a new generation of stents that adapt exactly to the changes in diameter of the coronary arteries during the post-myocardial infarction phase.

This new generation of stent offers a safer treatment option for patients. It has been introduced in response to cardiologists’ demands for improved stent solutions for AMI, a major cardiovascular pathology which is widespread across western countries.

STENTYS has already led regulatory studies and proved its products efficiency. They have received the CE, allowing sales in the European Union.

The filing of the "Document de Base" is the first step towards an initial public offering of shares by STENTYS which is expected to take place shortly, subject to market conditions after approval of the offer prospectus by the AMF.


The attention of investors is drawn to Section 4 “Risk Factors” of the “Document de Base” registered with the AMF and in particular the specific risks related to the Company’s two licensing deals.

More information about the company on the website: www.stentys.com

Citigate Dewe Rogerson

Contacts
Agnès Villeret (investors) - Tel: +33 (0)1 53 32 78 95 - agnes.villeret@citigate.fr
Lucie Larguier (press) - Tel : +33 (0)1 53 32 84 75 - lucie.larguier@citigate.fr

Notice

This announcement does not, and shall not under any circumstances, constitute a public offering or an invitation to the public in connection with any offer of securities. No public offering of securities will be conducted in France or abroad prior to the delivery by the AMF of a visa on a prospectus that complies with the provisions of Directive 2003/71/CE.

The publication of this press release in certain countries may violate applicable regulations. The information contained therein does not constitute an offer for securities in the United States, Canada, Australia, Italy or Japan or in any other jurisdiction. This press release should not be published, transmitted or distributed, directly or indirectly, into the United States, Canada, Australia, Italy or Japan.

This document is not an offer for sale of the shares of STENTYS in the United States. The shares of STENTYS may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. STENTYS does not intend to register any portion of the offering in the United States or to conduct a public offering of the shares in the United States.

This document contains forward-looking statements. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de base, changes in economic conditions, the financial markets or the markets in which STENTYS operates.